![]()
|
|
||||||||
J. Biol. Chem., Vol. 276, Issue 12, 8875-8883, March 23, 2001
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the University Hospital Freiburg, Department of Internal
Medicine II/Molecular Biology, Hugstetter Str. 55, D-79106 Freiburg, Germany
Hepatitis B virus (HBV), a small DNA containing
virus that replicates via reverse transcription, causes acute and
chronic B-type hepatitis in humans. The limited success of current
therapies for chronic infection has prompted exploration of alternative strategies. Capsid-targeted viral inactivation is a conceptually powerful approach that exploits virion structural proteins to target a
degradative enzyme specifically into viral particles. Its principal
feasibility has been demonstrated in retroviral model systems but not
yet for a medically relevant virus outside the retrovirus family.
Recently, we found that C proximal fusion to the HBV capsid protein of
the Ca2+-dependent nuclease (SN) from
Staphylococcus aureus yields a chimeric protein, coreSN,
that in Escherichia coli coassembles with the wild-type
capsid protein into particles with internal SN domains. Here we show
that, in HBV co-transfected human hepatoma cells, less than 1 coreSN
protein per 10 wild-type core protein subunits reduced titers of
enveloped DNA containing virions by more than 95%. The antiviral
effect depends on both an enzymatically active SN and on the core
domain. CoreSN does not block assembly of RNA containing nucleocapsids
but interferes with proper synthesis of viral DNA inside the capsid, or
leads to rapid DNA degradation. Our data suggest an intracellular
nuclease activation that, owing to the characteristics of HBV
morphogenesis, is nonetheless highly virus specific. HBV may therefore
be particularly vulnerable to the capsid-targeted viral inactivation approach.
To whom correspondence should be addressed: University Hospital
Freiburg, Dept. of Internal Medicine II/Molecular Biology, Hugstetter
Str. 55, D-79106 Freiburg, Germany. Tel./Fax: 49-761-270-3507; E-mail:
nassal2@ukl.uni-freiburg.de.
This article has been cited by other articles:
![]() |
X. Lu, T. Tran, E. Simsek, and T. M. Block The Alkylated Imino Sugar, n-(n-Nonyl)-Deoxygalactonojirimycin, Reduces the Amount of Hepatitis B Virus Nucleocapsid in Tissue Culture J. Virol., November 15, 2003; 77(22): 11933 - 11940. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |